Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead Sciences 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead Sciences 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences

3Q Revenues: $1.4 billion (+30%)

3Q Earnings: $504 million (+27%)

YTD Revenues: $3.9 billion (+25%)
 
YTD Earnings: $1.4 billion (+19%)

Comments: The company achieved record revenues in the quarter. Growth was driven by the company’s antiviral franchise, with sales up 39% to $1.2 billion, including strong performances by Atripla and Truvada, with sales up 77% to $427.6 million and 34% to $549.1 million, respectively. Viread sales were $156.0 million in the quarter (+5%). Sales of Hepsera increased 15% to $91.2 million, driven primarily by a favorable foreign exchange impact and sales growth in North America and certain European markets. Sales of AmBisome were up 6% to $72.9 million. Royalty, contract and other revenues were $32.8 million, down 66% due to lower Tamiflu royalties from Roche ($8.6 million in 3Q08 compared to $77.4 million in 3Q07). R&D expenses were $188.1 million in the quarter (+34%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters